A randomized intrapatient cross-over study to assess the efficacy of oxybutynin versus venlafaxine in REDucing hot FLASHes in women using endocrine therapy after breast cancer: the RED FLASH study.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507847-13-00

Enrollment

260

Registered

2024-04-09

Start date

2024-08-09

Completion date

Unknown

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Brief summary

Number and severity of hot flashes during 6-week therapy measured by the Hot Flash Diary on a daily basis.

Detailed description

Adverse events, sleep quality, quality of life, health status, anxiety and depression, cognitive function, sexual function, personal preference, adherence

Interventions

DRUGEXEMESTANE

DRUGGOSERELIN

DRUGVENLAFAXINE

DRUGLEUPRORELIN

DRUGOXYBUTYNIN

DRUGFULVESTRANT

DRUGLETROZOLE

DRUGTAMOXIFEN

DRUGANASTROZOLE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number and severity of hot flashes during 6-week therapy measured by the Hot Flash Diary on a daily basis.	—

Secondary

Measure	Time frame
Adverse events, sleep quality, quality of life, health status, anxiety and depression, cognitive function, sexual function, personal preference, adherence	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026